Cribstone Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Cribstone Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-75	Closed	-$12K	–	382
2021 Q2	$12K	Hold	75	–	–	0.01%	243
2021 Q1	$9K	Hold	75	–	–	0.01%	258
2020 Q4	$11K	Hold	75	–	–	0.01%	232
2020 Q3	$6K	Hold	75	–	–	﹤0.01%	227
2020 Q2	$6K	Hold	75	–	–	0.01%	249
2020 Q1	$3K	Hold	75	–	–	﹤0.01%	281
2019 Q4	$5K	Sell	75 -111	-60%	-$6.06K	﹤0.01%	307
2019 Q3	$8K	Hold	186	–	–	﹤0.01%	445
2019 Q2	$9K	Hold	186	–	–	﹤0.01%	454
2019 Q1	$7K	Hold	186	–	–	﹤0.01%	496
2018 Q4	$5K	Hold	186	–	–	﹤0.01%	554
2018 Q3	$8K	Buy	186 +75	+68%	+$3.93K	﹤0.01%	548
2018 Q2	$7K	Hold	111	–	–	﹤0.01%	570
2018 Q1	$5K	Buy	111 +21	+23%	+$867	﹤0.01%	593
2017 Q4	$2K	Hold	90	–	–	﹤0.01%	779
2017 Q3	$2K	Hold	90	–	–	﹤0.01%	666
2017 Q2	$1K	Hold	90	–	–	﹤0.01%	694
2017 Q1	$2K	Hold	90	–	–	﹤0.01%	680
2016 Q4	$2K	Buy	+90	New	+$1.68K	﹤0.01%	628

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cribstone Capital Management's CRSP Position: Q3 2021 in Review

Cribstone Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 75 shares — an estimated $12K sold.

Cribstone Capital Management first reported a position in CRSP in Q4 2016 and held it in 19 quarters. The position peaked at $12K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

Cribstone Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
Cribstone Capital Management sold 75 CRISPR Therapeutics shares in Q3 2021, an estimated $12K.
Cribstone Capital Management first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 19 quarters.
Cribstone Capital Management's CRISPR Therapeutics position peaked at $12K in Q2 2021.
473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Cribstone Capital Management's 13F filing for Q3 2021, filed 18 Nov 2021.